NASDAQ:ABSI Absci (ABSI) Stock Price, News & Analysis $3.60 -0.08 (-2.04%) As of 11:50 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Absci Stock (NASDAQ:ABSI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Absci alerts:Sign Up Key Stats Today's Range$3.52▼$3.7450-Day Range$2.34▼$4.1852-Week Range$2.01▼$6.33Volume3.64 million shsAverage Volume4.81 million shsMarket Capitalization$539.02 millionP/E RatioN/ADividend YieldN/APrice Target$7.98Consensus RatingModerate Buy Company Overview Absci Corporation (NASDAQ: ABSI) is a biotechnology company that applies machine learning, synthetic biology and automation to accelerate the discovery and development of protein-based therapeutics. The company’s Integrated Drug Creation® (IDC®) platform is designed to identify and produce novel antibody and enzyme candidates at speeds and scales that traditional biopharma discovery methods cannot match. Absci works with pharmaceutical and biotechnology partners to generate, screen and optimize protein molecules for a wide range of therapeutic applications. The core of Absci’s offering is its end-to-end discovery engine, which combines proprietary algorithms, high-throughput laboratory automation and a deep learning framework. By integrating AI-driven protein design with advanced screening processes, the company seeks to rapidly advance promising biologic candidates from concept through lead optimization. Absci’s platform supports research in areas such as oncology, immunology and metabolic disease, providing partners with drug-like protein candidates and data insights that can de-risk preclinical development. Founded in 2018 and headquartered in Seattle, Washington, Absci maintains collaborative relationships with multiple global pharmaceutical organizations and operates additional research facilities in the United States. The company’s leadership team brings together experts in protein engineering, data science and drug development, aiming to transform biologics discovery through technological innovation. As Absci continues to expand its pipeline partnerships and platform capabilities, it remains focused on delivering scalable solutions for the next generation of protein therapeutics.AI Generated. May Contain Errors. Read More Absci Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreABSI MarketRank™: Absci scored higher than 61% of companies evaluated by MarketBeat, and ranked 393rd out of 948 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingAbsci has received a consensus rating of Moderate Buy. The company's average rating score is 2.71, and is based on 6 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialAbsci has a consensus price target of $7.98, representing about 119.5% upside from its current price of $3.64.Amount of Analyst CoverageAbsci has only been the subject of 4 research reports in the past 90 days.Read more about Absci's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Absci are expected to grow in the coming year, from ($0.89) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Absci is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Absci is -3.88, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbsci has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Absci's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted25.37% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Absci has recently increased by 4.87%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAbsci does not currently pay a dividend.Dividend GrowthAbsci does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted25.37% of the float of Absci has been sold short.Short Interest Ratio / Days to CoverAbsci has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Absci has recently increased by 4.87%, indicating that investor sentiment is decreasing. News and Social Media3.1 / 5News Sentiment0.54 News SentimentAbsci has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Absci this week, compared to 4 articles on an average week.Search Interest34 people have searched for ABSI on MarketBeat in the last 30 days. This is an increase of 467% compared to the previous 30 days.MarketBeat Follows16 people have added Absci to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Absci insiders have bought more of their company's stock than they have sold. Specifically, they have bought $433,788.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders10.49% of the stock of Absci is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions52.05% of the stock of Absci is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Absci's insider trading history. Receive ABSI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Absci and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ABSI Stock News HeadlinesAbsci (NASDAQ:ABSI) CAO Todd Bedrick Purchases 10,000 SharesSeptember 25, 2025 | insidertrades.comAbsci participates in a conference call with JPMorganOctober 10 at 7:53 PM | msn.comMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on some of the biggest winners of 2025.October 13 at 2:00 AM | Chaikin Analytics (Ad)JPMorgan Chase & Co. Initiates Coverage on Absci (NASDAQ:ABSI)October 3, 2025 | americanbankingnews.comJP Morgan Initiates Coverage of Absci (ABSI) with Overweight RecommendationOctober 2, 2025 | msn.comAbsci initiated with an Overweight at JPMorganOctober 2, 2025 | msn.comInsider Spends US$255k Buying More Shares In AbsciSeptember 27, 2025 | finance.yahoo.comAbsci Corporation (ABSI) Secures $64M Financing to Drive AI Drug Discovery Through 2028September 22, 2025 | finance.yahoo.comSee More Headlines ABSI Stock Analysis - Frequently Asked Questions How have ABSI shares performed this year? Absci's stock was trading at $2.62 at the beginning of 2025. Since then, ABSI stock has increased by 38.7% and is now trading at $3.6350. How were Absci's earnings last quarter? Absci Corporation (NASDAQ:ABSI) issued its earnings results on Tuesday, August, 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.05. The business had revenue of $0.59 million for the quarter, compared to analyst estimates of $1.39 million. Absci had a negative net margin of 2,737.94% and a negative trailing twelve-month return on equity of 60.21%. Read the conference call transcript. When did Absci IPO? Absci (ABSI) raised $200 million in an initial public offering (IPO) on Thursday, July 22nd 2021. The company issued 12,500,000 shares at $15.00-$17.00 per share. Who are Absci's major shareholders? Absci's top institutional shareholders include Voya Investment Management LLC (0.01%). Insiders that own company stock include Phoenix Venture Partners Ii Lp, Redmile Group, Llc, Zachariah Jonasson, Andreas Busch, Todd Bedrick and Menelas N Pangalos. View institutional ownership trends. How do I buy shares of Absci? Shares of ABSI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Absci own? Based on aggregate information from My MarketBeat watchlists, some other companies that Absci investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Arista Networks (ANET) and CrowdStrike (CRWD). Company Calendar Last Earnings8/12/2025Today10/13/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryBusiness Services Current SymbolNASDAQ:ABSI CIK1672688 Webwww.absci.com Phone360-949-1041FaxN/AEmployees210Year Founded2011Price Target and Rating Average Price Target for Absci$7.98 High Price Target$10.00 Low Price Target$5.89 Potential Upside/Downside+116.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)($0.94) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$103.11 million Net Margins-2,737.94% Pretax Margin-2,733.47% Return on Equity-60.21% Return on Assets-50.85% Debt Debt-to-Equity RatioN/A Current Ratio4.39 Quick Ratio4.39 Sales & Book Value Annual Sales$4.53 million Price / Sales121.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.56 per share Price / Book2.36Miscellaneous Outstanding Shares149,520,000Free Float133,838,000Market Cap$550.23 million OptionableOptionable Beta2.06 Social Links Analysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:ABSI) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Absci Corporation Please log in to your account or sign up in order to add this asset to your watchlist. Share Absci With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.